Even I was shocked when I saw this yesterday

I knew it was a good idea, but the move I saw surprised even me. --------------------------------------------------------------- *Sponsored by Lifewater Media, please see disclosures below All I can say is “WOW!” I introduced you to [RenovoRX]( (RNXT) yesterday, and even I was shocked at how well it performed. You saw it alongside of everyone else right at the market open, and then…. KABOOM! 💥 This chart I snapped on my phone at the close yesterday just about says it all (and check out what it PEAKED at)…  I mean, that escalated really quickly… This is what really gets my blood flowing as a trader! Seeing moves like this in a single day is why I really love trading small-cap stocks.  The moves can just be blistering when you land on the right idea. As I was digging around today, I noticed that Barchart has upgraded their overall buy rating on RNXT:   If you missed the email I sent out yesterday, here are some highlights on why I think you should take a look at RNXT… First of all, when I ran my custom EMA scan on RNXT, look at how powerful the signals have been (yesterday was a perfect example)… 💪 As you can see from the spots I circled above, when the EMA crossovers happen, it has been a signal of a reversal in trend, both higher and lower. Right now, you can clearly see that there is a bullish reversal for RNXT.  You never know how long this will last, of course, but if you go back and look at the previous times we saw a reversal signal like this, it has been extremely bullish. RNXT’s stock price actually made a new high for the year earlier this month – the day they released their annual report – so I knew something big was probably happening. 1) The stock has retreated around 40% since failing to make a new high. I think now is an excellent time to revisit this stock if you were looking at it then, or even better if this is the first time it has come across your trading radar. One of the things that I found extremely interesting is that RNXT is in a Phase III [clinical trial right now](. In fact, Benzinga reported last week that RNXT’s cancer treatment suggests a 6-month potential improvement in median overall survival with RenovoGem. (2) I have looked at probably a thousand small biotech companies over the years, and I can tell you that it is very rare for a company to make it to Phase III testing.  While a lot of time and research goes into the process, a vast majority of companies simply never make it past Phase II, and get a shot at the final study in a Phase III trial. (3) RNXT is one of those companies that beat the odds and are now in a Phase III study. [From their website](, you can read some very exciting news about this company.  Keep in mind that the total market cap is under a paltry $30 million, and consider what shareholders are getting here… RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Delivering targeted therapy via the RenovoTAMP platform safely and without transmission to non-targeted areas, is the primary focus for RenovoRx. The company’s patent portfolio currently includes eight US patents and one European patent for the technology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase I/II clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the Phase III TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. (4) When I see that a tiny company like this has so much to work with, it makes me think about what the upside potential could look like. Ok, I’ll admit that I am just a lowly stock trader, not an analyst, LOL.  But, I found someone who is an analyst, and he has a price target of $9 on RNXT. (5) Maxim Group analyst Dr. Jason McCarthy, Senior Managing Director, Head of Biotechnology Research Maxim Group. He received his doctoral degree in Biomedical Sciences at the Albert Einstein College of Medicine. Dr. McCarthy also holds a Master’s degree in both Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University. (6) SeekingAlpha agrees, and you can see that the average analyst target is over 260% higher than current levels, and all have a “buy” rating (7)… What I really care about, though, is the near-term trading potential when it comes time for me to look at a stock. I have to tell you, what I dug up on RNXT, in my opinion, really is impressive.  I don’t think I have seen a stock in a long time that racks up the kind of glowing “green lights” like this when it comes to the [technical trading outlook](. The recent overall company insight score from Yahoo?  Crushing it. Way above the sector score of just “20” right now. ✅ 8) Also, from Yahoo Finance, the automated outlook for short and mid-term trading indicators are unlike anything else when I checked it recently. ✅ (9) Going back to SeekingAlpha. They also have a proprietary “[momentum grade](” showing what stocks are hot at the moment. Well, right now RNXT is doing way better than I did on my tests in school!  ✅ (10) On top of that, RNXT is getting a nearly perfect score on the Barchart technical indicator ratings as well. ✅ (11) Another site I like to get information on the trading outlook from is Tickeron. This site looks at different past trends and gives you the odds of it happening again based on that. Pretty impressive stuff copied from their site… Bullish Trend Analysis The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNXT's RSI Oscillator exited the oversold zone, 7 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend: 88%. The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected. Following a +6.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in 55 of 64 cases, the price rose further within the following month. The odds of a continued upward trend: 86%. The Aroon Indicator entered an Uptrend today. In 9 of 9 cases where RNXT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend: 90%. (12) While I am more of a short-term trader, I really like to know [what the company outlook]( is before I make a trade.  Here is the projected timeline of what RNXT expects for the release of data around their studies (13): Bottom line, I found RNXT to be an amazing opportunity to look further into right now.  It definitely checks a lot of boxes for me when it comes to a balance of trading possibilities, fundamentals, and near-term trading indicators. For a stock with such a small market cap right now, I think it is clear that RNTX has a ton of potential ahead of them. Now, biotech stocks are inherently risky. While I have seen some make moves of 1000% higher or more, some fail and become nearly worthless. Always spend some time [getting to know more about the company](, what they do, and the risks involved before you ever decide to trade a stock. A great place to get started would be right here on the [company website](. There are always risks to trading, of course. It’s up to you to decide if you think the risks outweigh the potential rewards for every trade you make. Good luck! I hope you have a great week of trading ahead of you! *Please see disclosures below RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Manage your email subscriptions.]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. If you have a current active subscription with Jason Bond Picks you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at JasonBondPicks.com. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.